Advertisement

Advertisement
Breast Cancer

Second-Line Endocrine Therapy With/Without Palbociclib Rechallenge in HR-Positive, HER2-Negative Advanced Breast Cancer

In a phase II trial (PALMIRA) reported in the Journal of Clinical Oncology, Llombart-Cussac et al evaluated whether palbociclib rechallenge with second-line alternative endocrine therapy may improve progression-free survival vs second-line alternative endocrine therapy alone.

 

Gynecologic Cancers

Risk of Gynecologic Cancers After 5 Years of Testosterone Use

Transmasculine and gender-diverse patients receiving testosterone as part of their hormone therapy may not be at an increased risk of developing gynecologic cancers in the first years of treatment, according to a recent study published by Vestering et al in eClinicalMedicine.

Colorectal Cancer

Retifanlimab-dlwr Approved for Anal Cancer

On May 15, the U.S. Food and Drug Administration (FDA) approved retifanlimab-dlwr (Zynyz), a PD-1–blocking monoclonal antibody, with carboplatin and paclitaxel for the first-line treatment of adults with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). The FDA also approved retifanlimab as a single agent for adults with locally recurrent or metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy.


Advertisement
Neuroendocrine Tumors

FDA Approves First Oral Therapy for Pheochromocytoma and Paraganglioma

On May 14, the U.S. Food and Drug Administration approved the oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor belzutifan (Welireg) for patients aged 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL). This represents the first FDA approval of an oral therapy for PPGL.

Legislation
Health-Care Policy

Patient Advocacy Groups: Health-Care Programs Are Lifelines—Not Line Items

Forty nonprofit, nonpartisan organizations issued a statement this week to the House Energy & Commerce and Ways & Means Committees in regard to budget cuts and policy changes affecting Medicaid and health-care marketplaces.

Advertisement
Advertisement




More Top Stories


Hematologic Malignancies

Rami S. Komrokji, MD, on Myelodysplastic Neoplasms: Classifying Risks Among Subsets of Disease

Multiple Myeloma

How Could So Many Physicians Have Failed Me?

Oya Gilbert The first sign that something was terribly wrong was in 2015, when I began to feel so fatigued that it was difficult to get out of bed even after 8 to 10 hours of sleep. I’ve been full of energy my whole life and couldn’t understand why I was so tired all the time. Then I began to ...

Advertisement

Risk of Gynecologic Cancers After 5 Years of Testosterone Use

Transmasculine and gender-diverse patients receiving testosterone as part of their hormone therapy may not be at an increased risk of developing gynecologic cancers in the first years of treatment, according to a recent study published by Vestering et al in eClinicalMedicine. Background Many...

Paolo Corradini, MD, on PMBCL and DLBCL: Comparing Outcomes With Axicabtagene Ciloleucel

Rakesh K. Jain, PhD, FAACR, Honored With 2025 AACR Award for Lifetime Achievement in Cancer Research

Rakesh K. Jain, PhD, FAACR The 2025 AACR Award for Lifetime Achievement in Cancer Research was presented to Rakesh K. Jain, PhD, FAACR, during the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago. This award honors individuals who have made significant...

Remembering Roswell Park Leader Thomas B. Tomasi, Jr, MD, PhD

Thomas B. Tomasi, Jr, MD, PhD Thomas B. Tomasi, Jr, MD, PhD, who led Roswell Park Comprehensive Cancer Center as President and Chief Executive Officer from 1986 to 1996, died on March 23 at age 97. His tenure marked a renaissance at Roswell Park that elevated it to a place among the nation’s...

Novel Prediction Model for Hearing Loss From Chemotherapy in Pediatric Patients With Cancer

In a study reported in the Journal of Clinical Oncology, Millstein et al attempted to develop a predictive model—Pediatric Holistic Evaluation of Auditory Risk (PedsHEAR)—for hearing loss associated with cisplatin chemotherapy in children and adolescents with cancer. Study Details PedsHEAR was...

Hematologic Malignancies
Leukemia

Nigel Russell, MD, on Acute Myeloid Leukemia: New Findings on FLAG-Ida and Gemtuzumab Ozogamicin

Keith T. Flaherty, MD, FAACR, Elected as AACR President-Elect for 2025–2026

Keith T. Flaherty, MD, FAACR The members of the American Association for Cancer Research (AACR) have elected Keith T. Flaherty, MD, FAACR, as the AACR President-Elect for 2025–2026. He will assume the Presidency in April 2026 at the AACR Annual Meeting in San Diego. Dr. Flaherty is Director...

Advertisement

Neoadjuvant Therapy for IBD-Related Rectal Cancer

Total neoadjuvant therapy of intensified chemoradiotherapy was shown to be less effective for treating patients with rectal cancer with inflammatory bowel disease (IBD) than those with sporadic rectal cancer, according to study findings presented during Digestive Disease Week 2025. However, there...

ASCO Post X Feed
Social Media Hub by Everwall